1. Home
  2. ABEO vs IMRX Comparison

ABEO vs IMRX Comparison

Compare ABEO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

HOLD

Current Price

$5.05

Market Cap

281.0M

Sector

Health Care

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$7.66

Market Cap

232.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABEO
IMRX
Founded
1974
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.0M
232.9M
IPO Year
1980
2021

Fundamental Metrics

Financial Performance
Metric
ABEO
IMRX
Price
$5.05
$7.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$18.20
$17.20
AVG Volume (30 Days)
2.8M
1.2M
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$324.71
N/A
P/E Ratio
$3.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.93
$1.10
52 Week High
$7.54
$10.08

Technical Indicators

Market Signals
Indicator
ABEO
IMRX
Relative Strength Index (RSI) 56.25 65.04
Support Level $4.37 $6.62
Resistance Level $5.17 $7.62
Average True Range (ATR) 0.32 0.56
MACD 0.12 0.08
Stochastic Oscillator 65.80 94.60

Price Performance

Historical Comparison
ABEO
IMRX

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: